About Cohera Medical
Cohera Medical is a medical device company that is developing a line of surgical adhesives. Cohera Medical's products are based on a chemical design that is resorbable, non-toxic, easy-to-use, and forms a strong bond between tissue layers. The Company's lead product, TissuGlu Surgical Adhesive, is designed to reduce fluid accumulation and the need for surgical drains in patients undergoing abdominoplasty (tummy tuck) and other plastic procedures that require the creation of large planar flaps of tissue. Cohera Medical is also developing surgical adhesives for use as bowel sealants, for hernia mesh fixation and for small bone fixation. Outside of the EU, TissuGlu Surgical Adhesive and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market.
Missing: Cohera Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cohera Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Cohera Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cohera Medical is included in 2 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Cohera Medical Patents
Cohera Medical has filed 9 patents.
Piperidines, Chemical reactions, Commodity chemicals, Organic reactions, Rearrangement reactions
Piperidines, Chemical reactions, Commodity chemicals, Organic reactions, Rearrangement reactions
Latest Cohera Medical News
Dec 30, 2020
News provided by Share this article This report on the global hemostasis and tissue sealing agents market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global hemostasis and tissue sealing agents market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global hemostasis and tissue sealing agents market during the forecast period. The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global hemostasis and tissue sealing agents market. Secondary research also included internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global hemostasis and tissue sealing agents market. The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global hemostasis and tissue sealing agents market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global hemostasis and tissue sealing agents market. The report delves into the competitive landscape of the global hemostasis and tissue sealing agents market. Key players operating in the global hemostasis and tissue sealing agents market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global hemostasis and tissue sealing agents market that have been profiled in this report. Key Questions Answered in Global Hemostasis and Tissue Sealing Agents Market Report What is the scope of growth of product companies in the global hemostasis and tissue sealing agents market? What will be the Y-o-Y growth of the global hemostasis and tissue sealing agents market between 2019 and 2027? What is the influence of changing trends in technologies on the global hemostasis and tissue sealing agents market? Will North America continue to be the most profitable market for hemostasis and tissue sealing agents providers? Which factors are anticipated to hamper the growth of the global hemostasis and tissue sealing agents market during the forecast period? Which are the leading companies in the global hemostasis and tissue sealing agents market? Research Methodology A unique research methodology has been utilized to conduct comprehensive research on the growth of the global hemostasis and tissue sealing agents market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions. Secondary methods referred to by analysts during the production of the global hemostasis and tissue sealing agents Market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of the study on the hemostasis and tissue sealing agents market as primary methods. These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the hemostasis and tissue sealing agents market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global hemostasis and tissue sealing agents market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching estimates on future prospects of the global hemostasis and tissue sealing agents market more reliably and accurately. Key Topics Covered:
Cohera Medical Frequently Asked Questions (FAQ)
When was Cohera Medical founded?
Cohera Medical was founded in 2003.
Where is Cohera Medical's headquarters?
Cohera Medical's headquarters is located at 227 Fayetteville St, Raleigh.
What is Cohera Medical's latest funding round?
Cohera Medical's latest funding round is Dead.
How much did Cohera Medical raise?
Cohera Medical raised a total of $147.49M.
Who are the investors of Cohera Medical?
Investors of Cohera Medical include Bradford Capital Partners, Pittsburgh Life Sciences Greenhouse, KKR, Pittsburgh Life Sciences Greenhouse, Kern Whelan Capital and 5 more.
Who are Cohera Medical's competitors?
Competitors of Cohera Medical include OrthAlign, Mercator MedSystems, REGENESIS BIOMEDICAL, Acelity, Calibra Medical and 12 more.
Compare Cohera Medical to Competitors
Regenesis is engaged in the development, manufacturing, and sale of biomedical devices that promote healing and skin wound closure more quickly and cost-effectively than existing standards of wound treatment. The company's devices are based on its Cell Proliferation Induction (CPI) technology, in which electromagnetic signals trigger the repair and regeneration of soft tissue cells.
Wadsworth Medical Technologies has developed a needle-less wound closure system known as the DermaLOC. The product uses next-generation adhesives and was originally designed for the MIT $50K Competition. The company was founded in 2005 by Dr. Andrew Fox, Dr. Daniel Risking and Jim Mills (Mr. Mills is no longer with the company).
Molnlycke Health Care is a manufacturer of single-use surgical and wound care products. The company's products help patients feel less pain and aid healthcare professionals to safer and more efficient surgery.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
ClearMedical is a distributor of remanufactured brand name surgical devices. ClearMedical aims to drive cost savings by selling high-volume, disposable, FDA approved laparoscopic, arthroscopic, and general surgical devices at reduced prices. The company collects used Single-Use-Devices (SUDs) from hospitals, reprocesses them consistent with FDA approvals, and sells them to hospitals and surgery centers wanting to reduce supply acquisition costs. The company's device list includes harmonic scalpels from Ethicon, trocars from Ethicon, US Surgical (AutoSuture), laparoscopic instruments from Ethicon, US Surgical (AutoSuture), clip appliers from ethicon, US Surgical (AutoSuture), linear cutter and staplers from Ethicon, and bone shavers from Linvatec, Smith & Nephew, and Stryker.
Developing, manufacturing, selling and exporting transcutaneousndevices which will put physiologically active substances intonsubcutaneous tissue applying the theory of electrophoresis. Developing, manufacturing, selling, exporting and importing cosmetic devices, health enhancement devices and medical devices. nnDeveloping, manufacturing, selling, exporting and importing cosmetics. All businesses that are incidental or related to the businesses stated nin the preceding items.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.